Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1, randomized placebo‐controlled, double‐blind, 3‐way complete crossover study comparing effect of macimorelin 2.0 mg/kg with placebo and moxifloxacin 400 mg

Next Previous
Trial Profile

A phase 1, randomized placebo‐controlled, double‐blind, 3‐way complete crossover study comparing effect of macimorelin 2.0 mg/kg with placebo and moxifloxacin 400 mg

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Macimorelin (Primary) ; Moxifloxacin
  • Indications Somatotropin deficiency
  • Focus Pharmacodynamics
  • Sponsors AEterna Zentaris GmbH

Most Recent Events

  • 30 Sep 2020 New trial record
  • 01 Jan 2020 Primary endpoint (baseline-corrected differences of QTcF values between macimorelin and placebo) has been met.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top